Recent News

• 08.03.2026 - Pelthos Therapeutics to Report Second Quarter 2026 Financial Results on August 13, 2026
• 07.24.2026 - Pelthos Therapeutics Announces 2026 Annual Meeting of Stockholders
• 06.30.2026 - Pelthos Therapeutics Added to Russell 3000E™ Growth Benchmark, Russell Microcap® and Russell Microcap® Growth Benchmark Indexes
• 05.28.2026 - Pelthos Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
• 05.14.2026 - Pelthos Therapeutics Announces First Quarter 2026 Financial Results
• 05.01.2026 - Pelthos Therapeutics to Report First Quarter 2026 Financial Results on May 14, 2026
• 04.14.2026 - Pelthos Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium
• 04.10.2026 - Pelthos Therapeutics Announces CFO Transition
• 03.31.2026 - Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain
• 03.19.2026 - Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results

Recent Filings

• 05.01.2024 - 8-K Current report
• 05.01.2024 - EFFECT Notice of Effectiveness
• 05.01.2024 - EFFECT Notice of Effectiveness
• 05.01.2024 - EFFECT Notice of Effectiveness
• 05.01.2024 - EFFECT Notice of Effectiveness
• 05.01.2024 - EFFECT Notice of Effectiveness
• 05.01.2024 - EFFECT Notice of Effectiveness
• 05.01.2024 - EFFECT Notice of Effectiveness
• 05.01.2024 - EFFECT Notice of Effectiveness
• 05.01.2024 - POS AM Post-Effective amendments for registration statement